These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33648379)

  • 1. Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective?
    Westphal ES; Aladeen T; Vanini D; Rainka M; McCadden K; Gengo FM; Bates V
    J Pharm Pract; 2022 Aug; 35(4):536-540. PubMed ID: 33648379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.
    Jeong YH; Koh JS; Kang MK; Ahn YJ; Kim IS; Park Y; Hwang SJ; Kwak CH; Hwang JY
    Korean J Intern Med; 2010 Jun; 25(2):154-61. PubMed ID: 20526388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.
    Komosa A; Siller-Matula JM; Kowal J; Lesiak M; Siniawski A; Mączyński M; Michalak M; Mularek-Kubzdela T; Grajek S
    Platelets; 2015; 26(1):43-7. PubMed ID: 24499166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel.
    Sambu N; Radhakrishnan A; Curzen N
    J Cardiovasc Pharmacol; 2012 Dec; 60(6):495-501. PubMed ID: 23232787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel generic formulations in the era of new antiplatelets: a systematic review.
    Tsoumani ME; Kalantzi KI; Goudevenos IA; Tselepis AD
    Curr Vasc Pharmacol; 2014; 12(5):766-77. PubMed ID: 23885646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolomics and platelet aggregometry between Plavix and generic clopidogrel in cats: a pilot study.
    Malkawi M; Woolcock AD; Lee PM; Court MH; Moore GE; Hogan DF
    J Feline Med Surg; 2019 Oct; 21(10):951-958. PubMed ID: 30427274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
    Seo KW; Tahk SJ; Yang HM; Yoon MH; Shin JH; Choi SY; Lim HS; Hwang GS; Choi BJ; Park JS; Shin JS; Lee YH; Choi YW; Park SJ; Jin XJ
    Clin Ther; 2014 Nov; 36(11):1588-94. PubMed ID: 25218311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects.
    Kim BH; Kim JR; Lim KS; Shin HS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Drug Investig; 2012 Dec; 32(12):817-26. PubMed ID: 23026843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography.
    Srimahachota S; Rojnuckarin P; Udayachalerm W; Buddhari W; Chaipromprasit J; Lertsuwunseri V; Akkawat B; Jirapattrathamrong S
    J Med Assoc Thai; 2012 Dec; 95(12):1495-500. PubMed ID: 23390778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome.
    Ko DT; Krumholz HM; Tu JV; Austin PC; Stukel TA; Koh M; Chong A; de Melo JF; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2018 Mar; 11(3):e004194. PubMed ID: 29535091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    Lee S; Lee HY; Park KW; Kang HJ; Koo BK; Kim HS; Choi DJ; Kim MA; Oh BH
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):413-24. PubMed ID: 23913405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
    Syvolap VV; Franskavichene LV; Golukhova EZ; Serebruany VL
    Cardiology; 2014; 129(2):103-5. PubMed ID: 25227134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Oberhänsli M; Lehner C; Puricel S; Lehmann S; Togni M; Stauffer JC; Baeriswyl G; Goy JJ; Cook S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):587-92. PubMed ID: 23177487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
    Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
    Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
    Phankingthongkum R; Panchavinnin P; Chinthammitr Y; Tresukosol D; Chotinaiwattarakul C; Tungsubutra W; Wongpraparut N; Kitrattana B; Leewanun P
    J Med Assoc Thai; 2013 May; 96(5):538-43. PubMed ID: 23745307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Original and generic clopidogrel: A comparison of antiplatelet effects and active metabolite concentrations in patients without polymorphisms in the ABCB1 gene and the allele variants CYPC19*2 and *3.
    Wójcik T; Szymkiewicz P; Ściborski K; Łukaszewski M; Onisk G; Mysiak A; Gamian A; Wiśniewski J; Dobosz T; Lebioda A; Jonkisz A; Protasiewicz M
    Adv Clin Exp Med; 2021 May; 30(5):485-489. PubMed ID: 33974752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris.
    Hajizadeh R; Ghaffari S; Ziaee M; Shokouhi B; Separham A; Sarbakhsh P
    J Cardiovasc Thorac Res; 2017; 9(4):191-195. PubMed ID: 29391931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.